Vilobelimab (USAN);
Gohibic (TN)

C6456H9976N1716O2054S44

145815.6633

145905.49

(Heavy chain)
QVQLQQSGPQ LVRPGTSVKI SCKASGYSFT TFWMDWVKQR PGQGLEWIGR IDPSDSESRL
DQRFKDRATL TVDKSSSTVY MQLSSPTSED SAVYYCARGN DGYYGFAYWG QGTLVTVSSA
STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPSCPA PEFLGGPSVF
LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
VFSCSVMHEA LHNHYTQKSL SLSLGK
(Light chain)
DIVLTQSPAS LAVSLGQRAT ISCKASQSVD YDGDSYMKWY QQKPGQPPKL LIYAASNLQS
GIPARFSGSG SGTDFTLNIH PVEEEDAATY YCQQSNEDPY TFGGGTKLEI KRTVAAPSVF
IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
(Disulfide bridge: H22-H96, H133-L218, H146-H202, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'133-L'218, H'146-H'202, H'260-H'320, H'366-H'424, L23-L92, L138-L198, L'23-L'92, L'138-L'198)

Anti-inflammatory, Anti-complement C5a antibody

FDA has issued an EUA for the emergency use of GOHIBIC for the treatment of coronavirus disease 2019 (COVID-19)Treatment of hidradenitis suppurativa, ANCA- associated vasculitis, pyoderma gangrenosum and chronic inflammatory conditions

C5 (C5a) [HSA:727] [KO:K03994]